La vendita allo scoperto per Aclaris Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Aclaris Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Aclaris Therapeutics (NASDAQ:ACRS) Azioni, Report sulle vendite allo scoperto

Aclaris Therapeutics

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics Inc

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) with a Neutral.

News

Reiteration

Analyst Ratings

ACRS

HC Wainwright & Co. Reiterates Neutral on Aclaris Therapeutics

The Phase 2a trial is an open-label study to investigate the safety, tolerability, pharmacokinetics, efficacy, and pharmacodynamics of ATI-2138 administered over 12 weeks in patients with moderate to severe atopic dermatitis. Aclaris&#39; planned enrollment for this trial is approximately 15 subjects, and the trial will be conducted in the United States. The primary endpoints are safety-related parameters. Secondary endpoints include Eczema Area and Severity Index (EASI) response measures, including EASI-50, EASI-75, and EASI-90, Validated Investigator Global Assessment (vIGA) response, body surface area (BSA)&nbsp;response and other pertinent efficacy related measures. Aclaris expects topline data from this trial in the first half of 2025

Aclaris Therapeutics Doses First Patient In Phase 2a Trial Of ATI-2138 For Moderate To Severe Atopic Dermatitis

Biotech

Earnings

Guidance

Health Care

General

Aclaris' Cash, Cash Equivalents And Marketable Securities Of $149.9M As Of June 30, 2024 And $26.5M From Sale Of Olumiant Royalties And Milestones Will Be Sufficient To Fund Its Operations Into 2028

Aclaris Therapeutics Q2 2024 GAAP EPS $(0.15) Beats $(0.20) Estimate, Sales $2.766M Beat $1.818M Estimate

The Dow Jones index closed higher by more than 100 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">BranchOut Food</h3>
<ul>
<li>The Trade: BranchOut Food Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOF#NASDAQ">BOF</a>) Director Byron Riche Jones <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 41,755 shares at</a> an average price of $0.99. To acquire these shares, it cost around $41,337.</li>
<li>What's Happening: On June 26, Branchout Food announced the pricing of its $1.4 million underwritten public offering of 1.75 million shares of common stock at $0.80 per share.</li>
<li>What BranchOut Food Does: Branchout Food inc is engaged in the development, marketing, sale, and distribution of plant-based, dehydrated fruit and vegetable snacks and powders.</li>
</ul>
<h3 class="wp-block-heading">Innovative Food Holdings</h3>
<ul>
<li>The Trade: Innovative Food Holdings, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/IVFH#OTC">IVFH</a>) Director Denver Johnson Smith <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 350,000 shares at</a> an average price of $1.20. To acquire these shares, it cost around $420,000.</li>
<li>What's Happening: On May 14, the company said revenues in the first quarter fell 5.7% to $15.7 million.</li>
<li>What Innovative Food Holdings Does: Innovative Food Holdings Inc through its subsidiaries is engaged in the distribution of perishables and specialty food products.</li>
</ul>
<h3 class="wp-block-heading">Crown Equity Holdings</h3>
<ul>
<li>The Trade: Crown Equity Holdings Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRWE#OTC">CRWE</a>) Marketing/Merger/Acq. Officer Jamie Hadfield <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 5,000 shares</a> at an average price of $0.25. The insider spent around $1,250 to buy those shares. </li>
<li>What's Happening: On June 14, Crown Equity named Ahmad Moradi as the new Chairman of the Board and Chief Strategic &amp; Science Officer.</li>
<li>What Crown Equity Holdings Does: Crown Equity Holdings Inc offers services to companies seeking to become public entities in the United States.</li>
</ul>
<h3 class="wp-block-heading">Aclaris Therapeutics</h3>
<ul>
<li>The Trade: Aclaris Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) 10% owner Braden Michael Leonard <a href="https://www.benzinga.com/quote/ACRS/analyst-ratings">acquired a total of 154,722 shares</a> at an average price of $1.31. The insider spent around $201,808 to buy those shares.</li>
<li>What's Happening: On July 16, Aclaris Therapeutics announced the sale of OLUMIANT royalties and milestones to OMERS Life Sciences for up to $31.5 million.</li>
<li>What Aclaris Therapeutics Does: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39881526/wall-streets-most-accurate-analysts-say-hold-these-3-utilities-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Say Hold These 3 Utilities Stocks With Over 5% Dividend Yields</a></li>
</ul>

Long Ideas

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

CRWE

IVFH

Aclaris Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying

WIIM

Aclaris Therapeutics shares are trading higher after the company announced the sale of OLUMIANT royalties and milestones to OMERS Life Sciences for up to $31.5 million.

- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities - - $26.5 Million Upfront Plus Up to $5.0 Million Milestone -

Asset Sales

Aclaris Therapeutics Sells OLUMIANT Royalties And Milestones To OMERS Life Sciences For Up To $31.5M

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Adma Biologics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adma#NASDAQ">ADMA</a>) one of those stocks right now? By taking a look at the stock&#39;s year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Adma Biologics is one of 1026 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Adma Biologics is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for ADMA&#39;s full-year earnings has moved 18% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, ADMA has returned 157.5% so far this year. In comparison, Medical companies have returned an average of 4.4%. As we can see, Adma Biologics is performing better than its sector in the calendar year.
Aclaris Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acrs#NASDAQ">ACRS</a>) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 21%.
For Aclaris Therapeutics, the consensus EPS estimate for the current year has increased 20.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Adma Biologics belongs to the Medical - Biomedical and Genetics industry, a group that includes 500 individual stocks and currently sits at #73 in the Zacks Industry Rank. Stocks in this group have lost about 5.3% so far this year, so ADMA is performing better this group in terms of year-to-date returns.
On the other hand, Aclaris Therapeutics belongs to the Medical - Drugs industry. This 181-stock industry is currently ranked #147. The industry has moved -7.4% year to date.
Investors interested in the Medical sector may want to keep a close eye on Adma Biologics and Aclaris Therapeutics as they attempt to continue their solid performance.
<a href="https://www.zacks.com/stock/news/2298444/is-adma-biologics-adma-stock-outpacing-its-medical-peers-this-year?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_1-2298444">To read this article on Zacks.com click here.</a>

ADMA

Is ADMA Biologics Stock Outpacing Its Medical Peers This Year?

The Dow Jones index closed higher by around 0.2% on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Aclaris Therapeutics</h3>
<ul>
<li>The Trade: Aclaris Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) 10% owner Braden Michael Leonard <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 352,397 shares</a> at an average price of $1.15. To acquire these shares, it cost around $405,894.</li>
<li>What's Happening: On May 7, Aclaris Therapeutics posted upbeat quarterly results.</li>
<li>What Aclaris Therapeutics Does: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States.</li>
</ul>
<h3 class="wp-block-heading">RENN Fund</h3>
<ul>
<li>The Trade: RENN Fund, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCG#NYSE">RCG</a>) President and CEO Murray Stahl <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 184 shares at</a> an average price of $1.74. To acquire these shares, it cost around $320.</li>
<li>What's Happening: RENN Fund shares rose around 5% over the past month.</li>
<li>What RENN Fund Does: RENN Fund Inc is active in the financial services domain.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39646161/top-3-financial-stocks-youll-regret-missing-in-q3">Top 3 Financial Stocks You&#8217;ll Regret Missing In Q3</a>

Aclaris Therapeutics And 1 Other Stock Under $5 Insiders Are Buying

The Dow Jones index closed lower by around 0.2% on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Aclaris Therapeutics</h3>
<ul>
<li>The Trade: Aclaris Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) 10% owner Braden Michael Leonard <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 1,611,200 shares</a> at an average price of $1.11. To acquire these shares, it cost around $1.78 million.</li>
<li>What's Happening: On May 7, Aclaris Therapeutics posted upbeat quarterly results.</li>
<li>What Aclaris Therapeutics Does: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States.</li>
</ul>
<h3 class="wp-block-heading">Zomedica</h3>
<ul>
<li>The Trade: Zomedica Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZOM#NYSE">ZOM</a>) Vice President of Sales Russell Kevin Klass <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 299,993 shares at</a> an average price of $0.16. To acquire these shares, it cost around $46,529.</li>
<li>What's Happening: On May 15, Zomedica announced the launch of Over-the-Air software and firmware update capability for its TRUFORMA point-of-care diagnostic platform.</li>
<li>What Zomedica Does: Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians.</li>
</ul>
<h3 class="wp-block-heading">Perspective Therapeutics</h3>
<ul>
<li>The Trade: Perspective Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATX#NASDAQ">CATX</a>) CEO Johan M. Spoor <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 100,000 </a>at an average price of $1.17. The insider spent around $117,430 to buy those shares. </li>
<li>What's Happening: On June 11, Perspective Therapeutics announced a 1-for-10 reverse stock split.</li>
<li>What Perspective Therapeutics Does: Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/06/39311150/top-3-tech-stocks-that-may-fall-off-a-cliff-this-month">Top 3 Tech Stocks That May Fall Off A Cliff This Month</a>

CATX

$1.8M Bet On This Health Care Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

<h3>Gainers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares rose 50.5% to $0.32 during Friday's after-market session. The market value of their outstanding shares is at $5.0 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares increased by 9.75% to $2.25. The market value of their outstanding shares is at $3.2 million. </li>
<li>Lucy Scientific Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSDI#NASDAQ">LSDI</a>) stock moved upwards by 6.89% to $0.93. The market value of their outstanding shares is at $1.6 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) shares increased by 6.4% to $1.33. The company's market cap stands at $5.6 million. </li>
<li>Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) shares rose 5.4% to $1.17. The market value of their outstanding shares is at $83.3 million. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) shares moved upwards by 4.98% to $0.56. The market value of their outstanding shares is at $39.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) stock fell 24.4% to $1.21 during Friday's after-market session. The market value of their outstanding shares is at $49.0 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) stock fell 14.04% to $0.84. The market value of their outstanding shares is at $14.7 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares decreased by 9.1% to $1.8. The company's market cap stands at $2.1 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock fell 7.75% to $0.29. The market value of their outstanding shares is at $3.5 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares decreased by 7.4% to $2.13. The company's market cap stands at $50.8 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) stock decreased by 7.18% to $0.29. The company's market cap stands at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADIL

BCLI

CYCC

DHAI

ISPC

LSDI

LUCY

ONMD

STSS

SXTP

WORX

12 Health Care Stocks Moving In Friday's After-Market Session

Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.29) by 17.24 percent. This is a 42.86 percent increase over losses of $(0.42) per share from the same period last year. The company reported quarterly sales of $2.40 million which beat the analyst consensus estimate of $1.37 million by 75.04 percent. This is a 5.14 percent decrease over sales of $2.53 million the same period last year.

Earnings Beats

Aclaris Therapeutics Q1 EPS $(0.24) Beats $(0.29) Estimate, Sales $2.40M Beat $1.37M Estimate

BioCryst Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcrx#NASDAQ">BCRX</a>) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.28 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 26.09%. A quarter ago, it was expected that this drugmaker would post a loss of $0.24 per share when it actually produced a loss of $0.28, delivering a surprise of -16.67%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
BioCryst, which belongs to the Zacks Medical - Drugs industry, posted revenues of $92.76 million for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by 8.37%. This compares to year-ago revenues of $68.78 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock&#39;s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management&#39;s commentary on the earnings call.
BioCryst shares have lost about 25.7% since the beginning of the year versus the S&amp;P 500&#39;s gain of 7.5%.
What&#39;s Next for BioCryst?
While BioCryst has underperformed the market so far this year, the question that comes to investors&#39; minds is: what&#39;s next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company&#39;s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for BioCryst: mixed. While the magnitude and direction of estimate revisions could change following the company&#39;s just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.16 on $96.97 million in revenues for the coming quarter and -$0.69 on $397.95 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Aclaris Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acrs#NASDAQ">ACRS</a>), is yet to report results for the quarter ended March 2024. The results are expected to be released on May 7.
This specialty pharmaceutical company is expected to post quarterly loss of $0.28 per share in its upcoming report, which represents a year-over-year change of +33.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Aclaris Therapeutics&#39; revenues are expected to be $1.99 million, down 21.4% from the year-ago quarter.
<a href="https://www.zacks.com/stock/news/2268441/biocryst-pharmaceuticals-bcrx-reports-q1-loss-tops-revenue-estimates?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_4-2268441">To read this article on Zacks.com click here.</a>

Earnings Misses

Small Cap

BCRX

BioCryst Pharmaceuticals Reports Q1 Loss, Tops Revenue Estimates

The Dow Jones index closed lower by over 400 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>Aclaris Therapeutics </h3>
<ul>
<li>The Trade: Aclaris Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acrs#NASDAQ">ACRS</a>) Director Andrew Kenneth William Powell <a href="https://www.benzinga.com/quote/PET/analyst-ratings"> acquired a total of 14,500 shares </a> an average price of $1.24. To acquire these shares, it cost around $17,955.</li>
<li>What&rsquo;s Happening: Aclaris Therapeutics reported its fourth-quarter earnings results on Feb. 27, 2024.</li>
<li>What Aclaris Therapeutics Does: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases.</li>
</ul>
<h3>Lumen Technologies</h3>
<ul>
<li>The Trade: Lumen Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lumn#NASDAQ">LUMN</a>) Director Laurie Siegel <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 30,000 shares at </a> at an average price of $1.60. To acquire these shares, it cost around $47,997.</li>
<li>What&rsquo;s Happening: On March 1, Lumen Technologies named Ryan Asdourian as its new Executive Vice President and Chief Marketing Officer.</li>
<li>What Lumen Technologies Does: With 450,000 route miles of fiber, Lumen Technologies is one of the United States&#39; largest telecommunications carriers serving global enterprises.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/03/37502472/campbell-soup-box-and-3-stocks-to-watch-heading-into-wednesday"> Campbell Soup, Box And 3 Stocks To Watch Heading Into Wednesday </a>
<h3>Personalis </h3>
<ul>
<li>The Trade: Personalis, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/psnl#NASDAQ">PSNL</a>) Director Woodrow A Myers Jr <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 10,000 shares </a> at an average price of $1.67. The insider spent around $16,700 to buy those shares.</li>
<li>What&rsquo;s Happening: On Feb. 28, Personalis posted downbeat quarterly results.</li>
<li>What Personalis Does: Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies.</li>
</ul>
&nbsp;
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

LUMN

PSNL

Lumen Technologies And 2 Other Stocks Under $2 Insiders Are Buying

Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) reported its Q4 earnings results on Tuesday, February 27, 2024 at 07:00 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Aclaris Therapeutics beat estimated earnings by 12.0%, reporting an EPS of $-0.3 versus an estimate of $-0.34.
Revenue was up $9.82 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.07 which was followed by a 1.0% drop in the share price the next day.
Here's a look at Aclaris Therapeutics's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.48</td>
<td>-0.45</td>
<td>-0.44</td>
<td>-0.45</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.41</td>
<td>-0.42</td>
<td>-0.42</td>
<td>-0.41</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.57M</td>
<td>1.90M</td>
<td>1.75M</td>
<td>1.99M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>9.28M</td>
<td>1.87M</td>
<td>2.53M</td>
<td>7.75M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Aclaris Therapeutics <a href="https://www.benzinga.com/quote/ACRS/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Aclaris Therapeutics: Q4 Earnings Insights

HC Wainwright has downgraded&nbsp;Aclaris Therapeutics Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>).
Earlier this month, the company released topline results from its Phase 2b study of ATI-1777, an investigational topical &#8220;soft&#8221; JAK 1/3 inhibitor, in patients with mild to&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36575186/aclaris-therapeutics-shares-fall-on-mixed-results-from-mid-stage-eczema-trial" rel="noreferrer noopener">severe atopic dermatitis (eczema)</a>.&nbsp;
The trial met the primary efficacy endpoint, the percent change from baseline in the Eczema Area and Severity Index (EASI) score at week 4, with statistical significance for patients treated with ATI-1777 2% twice-daily (BID) compared to patients treated with vehicle (69.7% versus 58.7% in the pooled vehicle group, p=0.035).&nbsp;
While not statistically superior, ATI-1777 2% once daily (QD) showed a trend toward significance (68.3% compared to 59.5% in vehicle, p=0.086).
The analyst observes that although the trial successfully achieved its primary goal with statistical significance, the once-daily treatment did not demonstrate statistically superior effectiveness compared to a placebo.&nbsp;
Additionally, the marginal difference in the primary endpoint between the twice-daily treatment and placebo suggests an unappealing commercial profile, especially noteworthy considering the competitive landscape.
HC Wainwright analysts Raghuram Selvaraju and Boobalan Pachaiyappan downgraded the&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/ACRS/analyst-ratings" rel="noreferrer noopener">stock from Buy to Neutral</a>.
Aclaris plans to seek a partner for the continued clinical development of ATI-1777. If this partnership occurs, the company&#8217;s rating and valuation will be reassessed.
Developing and successfully commercializing a twice-daily topical treatment for atopic dermatitis with a therapeutic impact that is not considered best-in-class could be challenging, the analyst writes.
This is particularly true given the current standard of care for atopic dermatitis, Dupixent (dupilumab) from&nbsp;Sanofi SA&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) and&nbsp;Regeneron Pharmaceuticals Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>).&nbsp;
Dupilumab is well-established in the market, boasting an impressive efficacy profile. Its twice-monthly subcutaneous injection dosing regimen is seen as significantly less burdensome compared to the application of a twice-daily topical product.&nbsp;
Additionally, there are other marketed drugs that, from HC Wainwright&#8217;s perspective, appear to be at least as effective as ATI-1777 has been so far.
Price Action: ACRS shares are up 9.2% at $1.24 on the last check Monday.

Analyst Color

Equities

Downgrades

REGN

Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades

Shares of CommScope Holding Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/comm#NASDAQ">COMM</a>) fell sharply during Monday&rsquo;s session.
B of A Securities analyst Tal Liani downgraded CommScope from Neutral to Underperform and lowered the price target from $2.1 to $2.
CommScope shares dipped 6.9% to $2.2150 on Monday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Sagimet Biosciences Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgmt#NASDAQ">SGMT</a>) shares jumped 135% to $15.99 after the company announced denifanstat in the Phase 2b FASCINATE-2 clinical trial achieved statistically significant results on the primary and multiple secondary endpoints.</li>
<li>Rail Vision Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvsn#NASDAQ">RVSN</a>) surged 54.5% to $2.1173. Rail Vision said its main line system has successfully obtained formal certifications for critical European Union railway standards.</li>
<li>Tenaya Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tnya#NASDAQ">TNYA</a>) gained 40% to $5.36.</li>
<li>Bullfrog AI Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bfrg#NASDAQ">BFRG</a>) jumped 37% to $6.70.</li>
<li>Lytus Technologies Holdings PTV. Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyt#NASDAQ">LYT</a>) surged 34.1% to $0.1376.</li>
<li>Fisker Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsr#NYSE">FSR</a>) shares gained 32.4% to $1.0450. Fisker filed a Form 8-K with the Securities and Exchange Commission regarding amendments with its 2025 convertible notes investor.</li>
<li>Fitell Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ftel#NASDAQ">FTEL</a>) gained 28.5% to $2.25.</li>
<li>Rumble Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rum#NASDAQ">RUM</a>) surged 25.6% to $4.51 after the company announced a partnership with Barstool Sports.</li>
<li>Eightco Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/octo#NASDAQ">OCTO</a>) jumped 24.9% to $0.5641.</li>
<li>Digital World Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dwac#NASDAQ">DWAC</a>) rose 24% to $32.70 after Ron DeSantis ended his presidential campaign. Digital World Acquisition Corp is the business combination partner of Trump Media &amp; Technology Group.</li>
<li>Fresh2 Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fres#NASDAQ">FRES</a>) gained 22.5% to $0.4900.</li>
<li>Taoping Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/taop#NASDAQ">TAOP</a>) rose 21.3% to $1.0298.</li>
<li>Coherus BioSciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chrs#NASDAQ">CHRS</a>) shares climbed 17.1% to $2.8577 after the company announced an agreement to divest ophthalmology franchise to Sandoz in $170 million upfront all cash deal.</li>
<li>ChargePoint Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/chpt#NYSE">CHPT</a>) rose 16.3% to $2.0250.</li>
<li>CXApp Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cxai#NASDAQ">CXAI</a>) gained 15% to $1.3098.</li>
<li>NuStar Energy L.P. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ns#NYSE">NS</a>) rose 14.2% to $20.59 after Sunoco announced it will acquire the company in an all-equity transaction valued at roughly $7.3 billion.</li>
<li>Upstart Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/upst#NASDAQ">UPST</a>) gained 13.3% to $37.06.</li>
<li>Spirit Airlines, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/save#NYSE">SAVE</a>) climbed 12.6% to $7.53 after the company and JetBlue Airways announced Friday that they will appeal a ruling blocking their proposed merger.</li>
<li>Affirm Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/afrm#NASDAQ">AFRM</a>) rose 11.3% to $46.98.</li>
<li>Fastly, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsly#NYSE">FSLY</a>) gained 10.3% to $20.69 after Citigroup upgraded the stock from Sell to Neutral and raised its price target from $11 to $20.</li>
<li>Aclaris Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acrs#NASDAQ">ACRS</a>) gained 7% to $1.22. Aclaris Therapeutics recently announced leadership changes as the company undertakes a strategic review of its business.</li>
<li>Genius Group Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gns#NYSE">GNS</a>) shares gained 6.4% to $0.3110 after gaining around 9% on Friday. Genius Group recently announced closing of $8.25 million public offering.</li>
<li>StoneCo Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stne#NASDAQ">STNE</a>) rose 5.7% to $18.00. Goldman Sachs analyst Tito Labarta upgraded StoneCo from Neutral to Buy and raised the price target from $12 to $21.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Virios Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/viri#NASDAQ">VIRI</a>) shares fell 39.2% to $0.4928. Virios Therapeutics announced plans to advance development of IMC-2 as treatment for symptoms associated with long-COVID.</li>
<li>Processa Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pcsa#NASDAQ">PCSA</a>) fell 30.9% to $3.11. Processa Pharmaceuticals recently announced plans to expand the development of Next Generation Capecitabine into the treatment of advanced or metastatic breast cancer.</li>
<li>Nuvve Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvve#NASDAQ">NVVE</a>) fell 25.8% to $2.85. Nuvve recently announced a 1-for-40 reverse stock split.</li>
<li>Hongli Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hlp#NASDAQ">HLP</a>) dipped 25.7% to $2.45.</li>
<li>Agrify Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agfy#NASDAQ">AGFY</a>) shares fell 19.8% to $0.8495 after declining around 23% on Friday. Agrify recently entered into a multi-million dollar sales agreement with Ocean Deep/Golden Lake Business Park.</li>
<li>NexImmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nexi#NASDAQ">NEXI</a>) declined 19.4% to $5.64.</li>
<li>Archer-Daniels-Midland Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/adm#NYSE">ADM</a>) fell 19.1% to $55.17 amid the company placing its CFO on leave due to an investigation studying accounting practices and procedures related to the company&#39;s nutrition segment. ADM said it now expects an adjusted earnings per share of $6.90 for the fiscal year ended Dec. 2023.</li>
<li>Calidi Biotherapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cldi#NASDAQ">CLDI</a>) dipped 18% to $0.91</li>
<li>Treasure Global Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tgl#NASDAQ">TGL</a>) shares fell 17.2% to $0.0929 after gaining 9% on Friday.</li>
<li>MMTec, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mtc#NASDAQ">MTC</a>) fell 14.6% to $2.09.</li>
<li>Intelligent Bio Solutions Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inbs#NASDAQ">INBS</a>) declined 13.4% to $0.2979. Intelligent Bio Solutions said that DGP Plc has selected the revolutionary portable intelligent fingerprinting drug screening system to enable in-house drug testing.</li>
<li>WiSA Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wisa#NASDAQ">WISA</a>) shares dipped 11.7% to $0.0940 after declining over 3% on Friday.</li>
<li>C3is Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ciss#NASDAQ">CISS</a>) fell 11.1% to $0.1202 after falling 6% on Wednesday. C3is shares dipped 64% on Friday after the company announced pricing of its $7 million upsized underwritten public offering.</li>
<li>Airspan Networks Holdings Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mimo#NASDAQ">MIMO</a>) declined 10.3% to $0.1895 after surging 24% on Friday. Airspan recently announced a partnership with GCT Semiconductor to develop an RF module.</li>
<li>B. Riley Financial, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rily#NASDAQ">RILY</a>) shares dipped 10.1% to $18.14. B. Riley Financial is reportedly facing a probe by U.S. authorities over its dealings with Brian Kahn, a key client linked to securities fraud, and the utilization of his assets to secure a loan from Nomura Holdings.</li>
<li>Gilead Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gild#NASDAQ">GILD</a>) fell 9.7% to $78.80 after the company reported its phase 3 study in metastatic non-small cell lung cancer did not meet primary endpoints.</li>
<li>e.l.f. Beauty, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/elf#NYSE">ELF</a>) declined 6.5% to $147.62. Morgan Stanley analyst Dara Mohsenian downgraded e.l.f. Beauty from Overweight to Equal-Weight and raised the price target from $137 to $168.</li>
<li>Worthington Enterprises, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wor#NYSE">WOR</a>) fell 5% to $52.47. Goldman Sachs analyst Susan Maklari initiated coverage on Worthington Enterprises with a Sell rating and announced price target of $50.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/01/36711116/how-to-earn-500-a-month-from-3m-stock-ahead-of-q4-earnings-print"> How To Earn $500 A Month From 3M Stock Ahead Of Q4 Earnings Print</a>

Intraday Update

AFRM

AGFY

BFRG

CHPT

CHRS

CISS

CLDI

COMM

CXAI

DWAC

FRES

FSLY

FTEL

GILD

Intelligent Bio Solutions Inc. - Common Stock

INBS

Airspan Networks Holdings Inc. Common Stock

MIMO

NEXI

NVVE

OCTO

PCSA

RILY

RVSN

SAVE

SGMT

STNE

TAOP

TNYA

UPST

VIRI

WISA

Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Shares of Coherus BioSciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chrs#NASDAQ">CHRS</a>) shares rose sharply in today&rsquo;s pre-market trading after the company announced an agreement to divest ophthalmology franchise to Sandoz in $170 million upfront all cash deal.
Coherus BioSciences shares jumped 22.1% to $2.98 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3>Gainers</h3>
<ul>
<li>Northann Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ncl#NYSE">NCL</a>) shares jumped 19.9% to $1.63 in pre-market trading after jumping over 25% on Friday.</li>
<li>HNR Acquisition Corp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hnra#NYSE">HNRA</a>) gained 15.4% to $2.48 in pre-market trading.</li>
<li>Porch Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prch#NASDAQ">PRCH</a>) gained 15.4% to $2.55 in pre-market trading.</li>
<li>TC Biopharm (Holdings) Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcbp#NASDAQ">TCBP</a>) surged 15% to $2.69 in pre-market trading after gaining over 10% on Friday. TC BioPharm recently regained compliance with Nasdaq minimum bid price requirement.</li>
<li>Remark Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mark#NASDAQ">MARK</a>) shares climbed 12.7% to $0.4340 in pre-market trading after falling more than 10% on Friday.</li>
<li>Unicycive Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/uncy#NASDAQ">UNCY</a>) shares gained 11.8% to $0.9690 in pre-market trading.</li>
<li>Aclaris Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acrs#NASDAQ">ACRS</a>) gained 10.5% to $1.26 in pre-market trading. Aclaris Therapeutics recently announced leadership changes as the company undertakes a strategic review of its business.</li>
<li>Genius Group Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gns#NYSE">GNS</a>) shares gained 9.4% to $0.3195 in pre-market trading after gaining around 9% on Friday. Genius Group recently announced closing of $8.25 million public offering.</li>
<li>Greenbrook TMS Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gbnh#NASDAQ">GBNH</a>) shares rose 8.9% to $0.2940 in pre-market trading. Greenbrook TMS raised $1.5 million in debt financing.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>B. Riley Financial, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rily#NASDAQ">RILY</a>) shares dipped 17.5% to $16.63 in pre-market trading. B. Riley Financial issued a statement in response to a Bloomberg news article published on Jan. 21, 2024.</li>
<li>Agrify Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agfy#NASDAQ">AGFY</a>) shares fell 14.2% to $0.91 in pre-market trading after declining around 23% on Friday. Agrify recently entered into a multi-million dollar sales agreement with Ocean Deep/Golden Lake Business Park.</li>
<li>HUB Cyber Security Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hubc#NASDAQ">HUBC</a>) shares fell 11.8% to $1.50 in pre-market trading after declining 11% on Friday.</li>
<li>Airspan Networks Holdings Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mimo#NASDAQ">MIMO</a>) declined 11.3% to $0.1872 in pre-market trading after surging 24% on Friday. Airspan recently announced a partnership with GCT Semiconductor to develop an RF module.</li>
<li>Treasure Global Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tgl#NASDAQ">TGL</a>) shares fell 10.9% to $0.10 in pre-market trading after gaining 9% on Friday.</li>
<li>Archer-Daniels-Midland Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/adm#NYSE">ADM</a>) fell 9.6% to $61.67 in pre-market trading after the company named Ismael Roig as Interim Chief Financial Officer. ADM said it now expects an adjusted earnings per share of $6.90 for the fiscal year ended Dec. 2023.</li>
<li>WiSA Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wisa#NASDAQ">WISA</a>) shares dipped 8.7% to $0.0973 in pre-market trading after declining over 3% on Friday.</li>
<li>Algoma Steel Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/astl#NASDAQ">ASTL</a>) shares declined 8.3% to $8.32 in pre-market trading. Algoma Steel Group announced that in the early hours of Jan. 20, 2024 there was a collapse of a structure supporting utilities piping at our coke-making plant.</li>
<li>Celularity Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/celu#NASDAQ">CELU</a>) shares declined 6.4% to $0.2750 in pre-market trading. For full year 2023 the company recently said it expects net sales percentage growth in the range of 22.7% to 26.6% year over year.</li>
<li>C3is Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ciss#NASDAQ">CISS</a>) fell 5.6% to $0.1277 after falling 6% on Wednesday. C3is shares dipped 64% on Friday after the company announced pricing of its $7 million upsized underwritten public offering.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/01/36710943/united-airlines-brown-brown-and-3-stocks-to-watch-heading-into-monday"> United Airlines, Brown &amp; Brown And 3 Stocks To Watch Heading Into Monday</a>

ASTL

CELU

GBNH

HNRA

HUBC

MARK

Nuveen Insured California Premium Fund Ii

PRCH

TCBP

UNCY

Why Coherus BioSciences Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Tango Therapeutics (TNGX – Research Report), Aclar...

Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Aclaris Therapeutics (ACRS) and Immunocore Holdings (IMCR)

Aclaris sells OLUMIANT royalties and milestones to OMERS life sciences

Aclaris Therapeutics (ACRS) has provided an update. Aclaris Therapeutics has struck a lucrative deal with OMERS, selling a portion of its future ro...

Aclaris Therapeutics Secures Deal with OMERS for OLUMIANT Royalties

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Aclaris Therapeutics (ACRS – Research Report), Celcuity (CELC – R...

Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS), Celcuity (CELC) and Intuitive Surgical (ISRG)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Aclaris Therapeutics (ACRS – Research Report). The compa...

H.C. Wainwright Keeps Their Hold Rating on Aclaris Therapeutics (ACRS)

Aclaris Therapeutics GAAP EPS of -$0.15, revenue of $2.8M

Leerink Partners analyst Thomas Smith maintained a Hold rating on Aclaris Therapeutics (ACRS – Research Report) yesterday and set a price target of...

Aclaris Therapeutics: Hold Rating Amidst Clinical Uncertainty and Strategic Review

H.C. Wainwright Reaffirms Their Hold Rating on Aclaris Therapeutics (ACRS)

H.C. Wainwright analyst Ram Selvaraju reiterated a Hold rating on Aclaris Therapeutics (ACRS – Research Report) today. The company's shares closed ...

Aclaris Therapeutics (ACRS) Gets a Hold from H.C. Wainwright

BTIG analyst Julian Harrison has maintained their neutral stance on ACRS stock, giving a Hold rating yesterday. Julian Harrison has given his Hold ...

Aclaris Therapeutics' ATI-2138: A Hold Rating Amidst Phase 2a Trials and Market Opportunity Assessment

CELC

IMCR

ISRG

TNGX

Press Releases

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Opinion

Biotech's Role in Addressing the Pancreatic Cancer Emergency

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Comments

Aclaris Therapeutics

Vendite allo scoperto

Aclaris Therapeutics (NASDAQ:ACRS) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO